News

Page Six

The Page Six headline claims Richard Norton ignored a nurse’s warning about peptide use before his sudden death at 75. The excerpt only repeats the headline and is too thin to establish further details or any link between peptide use and his death.

TMZ

TMZ's headline claims actor Richard Norton was warned about peptide dosage before his death. The excerpt only repeats the headline and is too thin to summarize further or establish any connection between peptides and his death.

The Mirror

The Mirror headline reports that a doctor issued a 'higher risk' warning concerning Omeprazole, Wegovy, and Metformin. The excerpt only repeats the headline and is too thin to summarize the risk, evidence, or people affected.

SSBCrack

The SSBCrack headline says an HHS plan for peptide drug access faces FDA opposition amid safety concerns. The excerpt only repeats the headline and is too thin to summarize the plan, opposition, or safety concerns in detail.

ABC News & Headlines – Australian Broadcasting Corporation

ABC's headline says an actor's death may be the first confirmed fatality linked to unapproved peptides. The provided excerpt only repeats the headline and is too thin to assess or summarize the reported link.

ClinicalTrials.gov: peptide AND aging

ClinicalTrials.gov lists a study of enicepatide (CT-388) in participants with overweight or obesity and Type 2 diabetes as completed. The randomized, double-blind, placebo-controlled trial evaluated efficacy and safety across three dose levels; the excerpt provides no results.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov-listed study is enrolling by invitation to assess whether geroprotective agents and a peptide-containing skin serum lower measured biological age. Researchers will use gene-activity measurements in skin and blood and assess safety and tolerability; the excerpt reports no results.

FDA press releases

According to the FDA, a federal court entered a consent decree against Gold Star Distribution, Inc. following persistent insanitary warehouse conditions. The Sept. 21, 2026 order stops distribution of FDA-regulated products until the company brings its operations into compliance with federal requirements.

FDA press releases

The FDA issued a direct final rule clarifying that non-animal methods can be used, where appropriate, to test the safety of drugs and biological products. The update concerns testing before these products are tried in humans.

ClinicalTrials.gov: elamipretide

ClinicalTrials.gov lists 4TAZPower as recruiting for a 72-week, Phase 3b/4 placebo-controlled trial of elamipretide in patients with genetically confirmed Barth syndrome. The listing says the trial aims to confirm efficacy following U.S. accelerated approval of FORZINITY based on improved knee extensor muscle strength.

ClinicalTrials.gov: elamipretide

The ClinicalTrials.gov listing describes ReNEW as an active Phase 3 trial of elamipretide for dry age-related macular degeneration that is no longer recruiting. The study compares elamipretide with placebo to evaluate efficacy, safety and pharmacokinetics.

ClinicalTrials.gov: survodutide

A ClinicalTrials.gov listing describes an active, non-recruiting study comparing survodutide with semaglutide in adults aged 18–65 with obesity. The randomized study tests whether survodutide improves energy use and fat breakdown, with participants followed for 8–10 months.

ClinicalTrials.gov: survodutide

ClinicalTrials.gov lists as completed a study testing survodutide (BI 456906) for weight loss in Japanese adults with obesity disease. Participants were randomly assigned to two survodutide groups or a placebo group; the provided excerpt does not report results.

ClinicalTrials.gov: survodutide

ClinicalTrials.gov lists a study of survodutide (BI 456906) in Chinese adults with overweight or obesity as completed. The trial randomly assigned participants to three groups to compare survodutide with placebo; the provided excerpt contains no results.

ClinicalTrials.gov: survodutide

ClinicalTrials.gov lists SYNCHRONIZE-MASLD as completed, a study testing survodutide against placebo for reducing liver fat and body weight in adults with overweight or obesity and presumed or confirmed NASH. Participants were assigned randomly to two groups; the provided excerpt contains no results.

ClinicalTrials.gov: survodutide

A ClinicalTrials.gov listing marks a study of BI 456906 in adults with and without kidney problems as completed. The study compared blood exposure across four kidney-function groups; the excerpt provides no results.

ClinicalTrials.gov: elamipretide

ClinicalTrials.gov lists an investigator-initiated study of Elamipretide for vision loss in Friedreich Ataxia (FRDA) as completed. The study aimed to evaluate safety, tolerability, and activity; the provided excerpt does not report results.

ClinicalTrials.gov: elamipretide

ClinicalTrials.gov lists SPIMD-301, a 48-week trial evaluating elamipretide in people with primary mitochondrial myopathy associated with nuclear DNA mutations, as completed. The randomized, double-blind, placebo-controlled study assessed efficacy and safety; the excerpt provides no results.

ClinicalTrials.gov: elamipretide

ClinicalTrials.gov lists the ReCLAIM-2 study of elamipretide as completed. The randomized, double-masked, placebo-controlled trial evaluated safety, efficacy and pharmacokinetics in people with age-related macular degeneration and non-central geographic atrophy; the excerpt provides no results.

ClinicalTrials.gov: elamipretide

ClinicalTrials.gov lists a randomized, double-blind crossover trial of elamipretide in subjects with Barth syndrome as completed. The trial evaluated safety, tolerability, and efficacy, but the provided excerpt contains no results.